Solvay has agreed a strategic collaboration with Ginkgo Bioworks, which the Belgian chemical giant said is aimed at “building the leading platform for cell programming and biosecurity.” Financial details were not disclosed.
The board of directors at US plant-based synthetic biology company Calyxt is evaluating potential strategic alternatives to maximize shareholder value, the company announced on Sept. 22. Options may include financing alternatives, merger, reverse merger, other business combinations, an asset sale or licensing. A timescale for completing the process has not yet been disclosed.
